Clinical Trials

Advanced Surgical Design and Manufacturer's (ASX: AMT) Pad Implant Featured on ABC Science Program "Catalyst"

🕔4/3/2008 12:35:31 PM

Leading Australian developer and manufacturer of prosthetic implants and medical devices, Advanced Surgical Design and Manufacture Limited (ASX: AMT) announces that this Thursday's episode of Catalyst (ABC TV) will feature the Limb Saving clinical trial currently being undertaken by AllVascular Pty Ltd and utilising the PAD access device developed with Advanced Surgical and exclusively manufactured by Advanced Surgical.

Read Full Article▸

Ventracor Limited (ASX:VCR) Announce Election of John Ward to Chairman

🕔4/3/2008 10:51:25 AM

Ventracor Limited (ASX: VCR)(PNK: VTCRY) announced today changes to the Board of Directors. John Massey has retired as a Director and Chairman of the Board. John Ward has been elected Chairman of the Board of Directors, and William Curran takes on the role of Chairman of the Audit, Risk and Compliance Committee.

Read Full Article▸

Ventracor (ASX:VCR) Announce US FDA Unconditional Approval of Destination Therapy Trial For LVAD

🕔3/17/2008 9:52:43 AM

Ventracor Limited (ASX: VCR)(ADR: VTCRY) announced today that the US Food and Drug Administration (FDA) has granted unconditional approval for the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).

Read Full Article▸

Ventracor Limited (ASX:VCR) Appoints Destination Therapy Trial Principal Investigator For LVAD

🕔3/13/2008 11:13:21 AM

Ventracor (ASX: VCR) announced today the appointment of Professor Mariell Jessup as Cardiology Principal Investigator of the US Destination Therapy Trial of the VentrAssist Left Ventricular Assist Device (LVAD).

Read Full Article▸

Cellestis Limited (ASX:CST) Announce a New Australian Blood Test Proven Six Times More Effective For Tuberculosis Control

🕔2/15/2008 12:39:56 PM

In a landmark study electronically published today in the American Journal of Respiratory and Critical Care Medicine, a blood test for detecting TB infection, QuantiFERON-TB Gold (QFT), has been shown to be six times more accurate than the conventional tuberculin skin test (TST) at predicting which tuberculosis (TB)-exposed individuals will go on to develop TB disease. This study has important implications for the worldwide effort to eradicate TB, as accurately indentifying TB-infected individuals allows health authorities to treat them before they develop disease, and the greater accuracy of the new test makes this more efficient as well as cheaper and safer.

Read Full Article▸

Ventracor Limited (ASX:VCR) Announces 200th VentraAssist LVAD (Left Ventricular Assist Device) Implant

🕔2/11/2008 2:09:27 PM

Ventracor (ASX: VCR) has implanted the 200th patient with its VentrAssist(tm) Left Ventricular Assist Device (LVAD)

Read Full Article▸

Ventracor (ASX:VCR) Announces European Approval for New Version VentrAssist LVAD

🕔12/19/2007 9:42:10 AM

Ventracor (ASX: VCR) today announced CE Marking approval for the next version of the VentrAssist(tm) left ventricular assist device (LVAD) which allows it to be marketed and sold in Europe.

Read Full Article▸

Banking & Finance

Read More

Oil Gas & Energy

Read More

Life Sciences

Read More

Social Media

Latest Headlines